Welcome to the international HTA database

Showing [16381 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2023	Scottish Health Technologies Group (SHTG)	Placental growth factor (PlGF)-based testing to help diagnose suspected preterm pre-eclampsia
2023	Scottish Health Technologies Group (SHTG)	The clinical effectiveness and cost effectiveness of a digital type 2 diabetes remission programme
2023	NIHR Public Health Research (PHR) programme	Impact of a social prescribing intervention in North East England on adults with type 2 diabetes: the SPRING_NE multimethod study
2023	NIHR Public Health Research (PHR) programme	A multicomponent psychosocial intervention to reduce substance use by adolescents involved in the criminal justice system: the RISKIT-CJS RCT
2023	NIHR Health Technology Assessment programme	Total ankle replacement versus ankle arthrodesis for patients aged 50–85 years with end-stage ankle osteoarthritis: the TARVA RCT
2023	NIHR Health Technology Assessment programme	Motivational support intervention to reduce smoking and increase physical activity in smokers not ready to quit: the TARS RCT
2023	Norwegian Institute of Public Health (NIPH)	Treatments for relapsing and/or refractory multiple myeloma. A health technology assessment
2023	Belgian Health Care Knowledge Centre (KCE)	Silicone adhesive multilayer foam dressings to prevent hospital-acquired pressure ulcers: a Belgian RCT-based economic evaluation
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Efgartigimod alfa (Myasthenia Gravis, AChR-antibody+)]
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Birch Bark Extract (treatment of wounds associated with epidermolysis bullosa (6 months and older))]
2023	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	Assessment of hip protectors for users at risk of falls
2023	NIHR Health Technology Assessment programme	Views of female genital mutilation survivors, men and health-care professionals on timing of deinfibulation surgery and NHS service provision: qualitative FGM Sister Study
2023	Agency for Care Effectiveness (ACE)	Echinocandins for treating invasive candidiasis
2023	Agency for Care Effectiveness (ACE)	Palivizumab for preventing serious lower respiratory tract disease caused by respiratory syncytial virus
2023	Agency for Care Effectiveness (ACE)	Inhaled corticosteroids with long acting beta-2 agonists for treating asthma
2023	Agency for Care Effectiveness (ACE)	Daratumumab for treating newly diagnosed light chain (AL) amyloidosis
2023	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Eladocagene exuparvovec (Aromatic-L-amino acid decarboxylase (AADC) deficiency, ≥ 18 months)]
2023	Health Information and Quality Authority (HIQA)	A rapid health technology assessment of gene expression profiling tests for guiding the use of adjuvant chemotherapy in early-stage invasive breast cancer
2023	Health Information and Quality Authority (HIQA)	Repatriation of paediatric haematopoietic stem cell transplant services to Ireland: a Health Technology Assessment
2023	Belgian Health Care Knowledge Centre (KCE)	Evaluation of digital medical technologies
2023	Penn Medicine Center for Evidence-based Practice (CEP)	Update: Clinical risk prediction tools for venous thromboembolism in medical patients
2023	Scottish Health Technologies Group (SHTG)	Bacteriophage therapy for patients with difficult to treat bacterial infections
2023	Health Technology Wales (HTW)	Renal denervation to treat people with resistant hypertension
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Update: Functioning and disability - An evidence map]
2023	Norwegian Institute of Public Health (NIPH)	177Lu-PSMA-617 for treatment of metastatic castration resistant prostate cancer: a health technology assessment
2023	Finnish Coordinating Center for Health Technology Assessment (FinCCHTA)	Evondos® medicine-dispensing service
2023	Ontario Health	Supplemental Screening as an Adjunct to Mammography for Breast Cancer Screening in People With Dense Breasts
2023	Health Information and Quality Authority (HIQA)	Health technology assessment of the addition of severe combined immunodeficiency (SCID) to the National Newborn Bloodspot Screening Programme
2023	Swedish Agency for Health Technology Assessment and Assessment of Social Services (SBU)	[Evaluation of taking mifepristone at home during a medical abortion]
2023	Canadian Agency for Drugs and Technologies in Health (CADTH)	Treatment of adult patients with chronic immune thrombocytopenia after failure of first-line therapies
2023	Health Technology Wales (HTW)	Multi-grip myoelectric upper-limb prosthetics
2023	Health Technology Wales (HTW)	Robot-assisted thoracic surgery
2023	NIHR Health Services and Delivery Research programme	The effectiveness and acceptability of multimedia information when recruiting children and young people to trials: the TRECA meta-analysis of SWATs
2023	NIHR Health Technology Assessment programme	A pragmatic, multicentre, double-blind, placebo-controlled randomised trial to assess the safety, clinical and cost-effectiveness of mirtazapine and carbamazepine in people with Alzheimer’s disease and agitated behaviours: the HTA-SYMBAD trial
2023	NIHR Public Health Research (PHR) programme	Behavioural intervention to reduce sexually transmitted infections in people aged 16–24 years in the UK: the safetxt RCT
2023	NIHR Health Technology Assessment programme	Antibiotics for lower respiratory tract infection in children presenting in primary care: ARTIC PC RCT
2023	NIHR Health Technology Assessment programme	Ulipristal acetate versus levonorgestrel-releasing intrauterine system for heavy menstrual bleeding: the UCON randomised controlled trial and mechanism of action study
2023	NIHR Health Technology Assessment programme	Adjunctive medication management and contingency management to enhance adherence to acamprosate for alcohol dependence: the ADAM trial RCT
2023	NIHR Health Technology Assessment programme	Integration, effectiveness and costs of different models of primary health care provision for people who are homeless: an evaluation study
2023	NIHR Health Technology Assessment programme	Evaluation of the Healthy Start Voucher Scheme in UK: a natural experiment using the Growing Up in Scotland record linkage study and the Infant Feeding Survey
2023	NIHR Health Technology Assessment programme	One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT
2022	Centre intégré universitaire de santé et de services sociaux de la Capitale-Nationale (CIUSSS)	The use of social media and electronic communication in the delivery of youth protection services to young people in difficulty and their families
2022	Norwegian Institute of Public Health (NIPH)	Zephyr® valves system in the treatment of emphysema: a single technology assessment
2022	Health Information and Quality Authority (HIQA)	Budget impact analysis – National Clinical Guideline: Infection prevention and control
2022	Health Information and Quality Authority (HIQA)	Clinical and cost-effectiveness of healthcare-associated infection interventions: a systematic review
2022	Health Information and Quality Authority (HIQA)	Update processes for guidelines – systematic review
2022	Health Information and Quality Authority (HIQA)	International review of clinical guidelines and models of care for long COVID
2022	National Institute for Health and Care Excellence (NICE)	Freelite assays for diagnosing multiple myeloma and related conditions (terminated assessment). NICE diagnostics guidance 47
2022	National Institute for Health and Care Excellence (NICE)	EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules. NICE diagnostics guidance 46
2022	National Institute for Health and Care Excellence (NICE)	PredictSURE IBD and IBDX to guide treatment of Crohn's disease. NICE diagnostics guidance 45
2022	National Institute for Health and Care Excellence (NICE)	PLGF-based testing to help diagnose suspected preterm pre-eclampsia. NICE diagnostics guidance 49
2022	National Institute for Health and Care Excellence (NICE)	Sedaconda ACD-S for sedation with volatile anaesthetics in intensive care. NICE medical technologies guidance 65
2022	National Institute for Health and Care Excellence (NICE)	3C Patch for treating diabetic foot ulcers. NICE medical technologies guidance 66
2022	National Institute for Health and Care Excellence (NICE)	Prontosan for treating acute and chronic wounds. NICE medical technologies guidance 67
2022	National Institute for Health and Care Excellence (NICE)	UroShield for preventing catheter-associated urinary tract infections. NICE medical technologies guidance 69
2022	National Institute for Health and Care Excellence (NICE)	myCOPD for managing chronic obstructive pulmonary disease. NICE medical technologies guidance 68
2022	National Institute for Health and Care Excellence (NICE)	Sleepio to treat insomnia and insomnia symptoms. NICE medical technologies guidance 70
2022	National Institute for Health and Care Excellence (NICE)	Faecal microbiota transplant for recurrent Clostridioides difficile infection. NICE medical technologies guidance 71
2022	National Institute for Health and Care Excellence (NICE)	Magtrace and Sentimag system for locating sentinel lymph nodes for breast cancer. NICE medical technologies guidance 72
2022	National Institute for Health and Care Excellence (NICE)	GreenLight XPS for treating benign prostatic hyperplasia. NICE medical technologies guidance 74
2022	National Institute for Health and Care Excellence (NICE)	Optilume for treating recurrent bulbar urethral strictures. NICE medical technologies guidance 73
2022	National Institute for Health and Care Excellence (NICE)	Memokath 051 Ureter stent for ureteric obstruction. NICE medical technologies guidance 75
2022	National Institute for Health and Care Excellence (NICE)	KardiaMobile for detecting atrial fibrillation. NICE medical technologies guidance 64
2022	National Institute for Health and Care Excellence (NICE)	Microwave ablation for primary or metastatic cancer in the lung. NICE interventional procedures guidance 716
2022	National Institute for Health and Care Excellence (NICE)	Stereotactic radiosurgery for trigeminal neuralgia. NICE interventional procedures guidance 715
2022	National Institute for Health and Care Excellence (NICE)	Endoscopic balloon dilation for subglottic or tracheal stenosis. NICE interventional procedures guidance 719
2022	National Institute for Health and Care Excellence (NICE)	Intramedullary distraction for lower limb lengthening. NICE interventional procedures guidance 718
2022	National Institute for Health and Care Excellence (NICE)	Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach. NICE interventional procedures guidance 717
2022	National Institute for Health and Care Excellence (NICE)	Percutaneous insertion of a cystic duct stent after cholecystostomy for acute calculous cholecystitis. NICE interventional procedures guidance 720
2022	National Institute for Health and Care Excellence (NICE)	Liposuction for chronic lipoedema. NICE interventional procedures guidance 721
2022	National Institute for Health and Care Excellence (NICE)	Intramedullary distraction for upper limb lengthening. NICE interventional procedures guidance 722
2022	National Institute for Health and Care Excellence (NICE)	Liposuction for chronic lymphoedema. NICE interventional procedures guidance 723
2022	National Institute for Health and Care Excellence (NICE)	Personalised external aortic root support (PEARS) using mesh to prevent aortic root expansion and aortic dissection in people with Marfan syndrome. NICE interventional procedures guidance 724
2022	National Institute for Health and Care Excellence (NICE)	Supercapsular percutaneously assisted total hip arthroplasty for osteoarthritis. NICE interventional procedures guidance 726
2022	National Institute for Health and Care Excellence (NICE)	Endoanchoring systems in endovascular aortic aneurysm repair. NICE interventional procedures guidance 725
2022	National Institute for Health and Care Excellence (NICE)	Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus). NICE interventional procedures guidance 727
2022	National Institute for Health and Care Excellence (NICE)	Nerve graft for corneal denervation. NICE interventional procedures guidance 729
2022	National Institute for Health and Care Excellence (NICE)	Vertebral body tethering for idiopathic scoliosis in children and young people. NICE interventional procedures guidance 728
2022	National Institute for Health and Care Excellence (NICE)	Transcatheter tricuspid valve leaflet repair for tricuspid regurgitation. NICE interventional procedures guidance 731
2022	National Institute for Health and Care Excellence (NICE)	Transcatheter tricuspid valve annuloplasty for tricuspid regurgitation. NICE interventional procedures guidance 730
2022	National Institute for Health and Care Excellence (NICE)	Aortic remodelling hybrid stent insertion during surgical repair of an acute type A aortic dissection. NICE interventional procedures guidance 733
2022	National Institute for Health and Care Excellence (NICE)	Bioresorbable stent implantation to treat coronary artery disease. NICE interventional procedures guidance 732
2022	National Institute for Health and Care Excellence (NICE)	Superficial venous arterialisation for chronic limb threatening ischaemia. NICE interventional procedures guidance 736
2022	National Institute for Health and Care Excellence (NICE)	Transcutaneous electrical neuromuscular stimulation for urinary incontinence. NICE interventional procedures guidance 735
2022	National Institute for Health and Care Excellence (NICE)	Focal resurfacing implants to treat articular cartilage damage in the knee. NICE interventional procedures guidance 734
2022	National Institute for Health and Care Excellence (NICE)	Removal, preservation and subsequent reimplantation of ovarian tissue to prevent symptoms from the menopause. NICE interventional procedures guidance 738
2022	National Institute for Health and Care Excellence (NICE)	Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia. NICE interventional procedures guidance 737
2022	National Institute for Health and Care Excellence (NICE)	Neurostimulation of lumbar muscles for refractory non-specific chronic low back pain. NICE interventional procedures guidance 739
2022	National Institute for Health and Care Excellence (NICE)	YAG laser vitreolysis for symptomatic vitreous floaters. NICE interventional procedures guidance 741
2022	National Institute for Health and Care Excellence (NICE)	Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine. NICE interventional procedures guidance 740
2022	National Institute for Health and Care Excellence (NICE)	Extracorporeal shockwave therapy for calcific tendinopathy in the shoulder. NICE interventional procedures guidance 742
2022	National Institute for Health and Care Excellence (NICE)	Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules. NICE interventional procedures guidance 743
2022	National Institute for Health and Care Excellence (NICE)	Ab interno canaloplasty for open-angle glaucoma. NICE interventional procedures guidance 745
2022	National Institute for Health and Care Excellence (NICE)	Tunnelled peritoneal drainage catheter insertion for refractory ascites in cirrhosis. NICE interventional procedures guidance 746
2022	National Institute for Health and Care Excellence (NICE)	Esketamine nasal spray for treatment-resistant depression. NICE technology appraisal guidance 854
2022	National Institute for Health and Care Excellence (NICE)	Avatrombopag for treating primary chronic immune thrombocytopenia. NICE technology appraisal guidance 853
2022	National Institute for Health and Care Excellence (NICE)	Trifluridinetipiracil for treating metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after 2 or more treatments. NICE technology appraisal guidance 852
2022	National Institute for Health and Care Excellence (NICE)	Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancer. NICE technology appraisal guidance 851
2022	National Institute for Health and Care Excellence (NICE)	Amivantamab for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy. NICE technology appraisal guidance 850